PSI CRO has announced opening offices in South Korea.

“We are excited about the PSI office opening," said Eun-Kyoung Oh, PSI’s Clinical Operations Manager in Seoul. "It gives us a solid base for future growth and expansion in South Korea. Our growth is driven by many clinical trial requests from global sponsors in the areas of PSI’s core therapeutic expertise: infectious diseases, oncology, inflammatory bowel diseases, gastroenterology, multiple sclerosis and project in rare indications, both adult and pediatric. We are excited to respond to these requests with a robust, experienced and driven team of PSI-South Korea who value on-time delivery, commitment and service.”

PSI’s expansion into Asia Pacific started earlier in the year, when PSI opened offices in Sydney, Australia and will continue with PSI’s moving into new offices in Taipei in Taiwan. All along, PSI has been focused on strengthening its global capabilities of delivering clinical trial programs in a variety of therapeutic areas on time and on budget.

“Delivery and Service are at the core of PSI’s growth strategy," said Olga Alfonsova, Global Head of Corporate Development. "We have always grown through exceptional repeat and referral business, and continue to do so in 2017. The addition of several offices in Asia Pacific this year marks an important milestone for PSI. We are ready as never before to support global clinical trials, collecting data of high quality, while reaching planned timelines on schedule all over the world.”